_1777293978995_62445876.jpg&w=64&q=75){kind=small}
Bahrain Approves VigoVi for Obesity
The Health Regulatory Authority in the Kingdom of Bahrain has approved the licensing of "VigoVi" (Semaglutide) tablets for the treatment of obesity. This oral medication, classified as a GLP-1 therapy, marks an important step in enhancing the options available for obesity treatment in the country. It has been available in pharmacies since mid-September, making Bahrain the second Gulf country after the UAE and the fifth country worldwide to offer this medication. The drug addresses conditions associated with obesity and aims to improve public health, while adhering to safety principles and medical standards. This development is part of ongoing efforts to improve the healthcare system in Bahrain.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)